|
1
|
Chang AM, Maisel AS and Hollander JE:
Diagnosis of heart failure. Heart Fail Clin. 5:25–35. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li JD, Cheng AY, Huo YL, Fan J, Zhang YP,
Fang ZQ, Sun HS, Peng W, Zhang JS, Wang HP, et al: Bilateral renal
denervation ameliorates isoproterenol-induced heart failure through
downregulation of the brain renin-angiotensin system and
inflammation in rat. Oxid Med Cell Longev. 2016:35626342016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Díez J: Serelaxin: A novel therapy for
acute heart failure with a range of hemodynamic and non-hemodynamic
actions. Am J Cardiovasc Drugs. 14:275–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valbusa F, Agnoletti D, Scala L, Grillo C,
Arduini P, Bonapace S, Calabria S, Scaturro G, Mantovani A, Zoppini
G, et al: Non-alcoholic fatty liver disease and increased risk of
all-cause mortality in elderly patients admitted for acute heart
failure. Int J Cardiol. 265:162–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davarzani N, Sanders-van Wijk S, Karel J,
Maeder MT, Leibundgut G, Gutmann M, Pfisterer ME, Rickenbacher P,
Peeters R and Brunner-la Rocca HP: N-terminal pro-B-type
natriuretic peptide-guided therapy in chronic heart failure reduces
repeated hospitalizations-results from TIME-CHF. J Card Fail.
23:382–389. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Böhm M, Voors AA, Ketelslegers JM,
Schirmer SH, Turgonyi E, Bramlage P and Zannad F: Biomarkers:
Optimizing treatment guidance in heart failure. Clin Res Cardiol.
100:973–981. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aikawa T, Naya M, Obara M, Manabe O,
Tomiyama Y, Magota K, Yamada S, Katoh C, Tamaki N and Tsutsui H:
Impaired myocardial sympathetic innervation is associated with
diastolic dysfunction in heart failure with preserved ejection
fraction: 11C-Hydroxyephedrine PET Study. J Nucl Med. 58:784–790.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qavi AH, Kamal R and Schrier RW: Clinical
use of diuretics in heart failure, cirrhosis, and nephrotic
syndrome. Int J Nephrol. 2015:9759342015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao Y, Tokudome T and Kishimoto I: Ghrelin
as a treatment for cardiovascular diseases. Hypertension.
64:450–454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kotecha D, Holmes J, Krum H, Altman DG,
Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P,
et al; Beta-Blockers in Heart Failure Collaborative Group, .
Efficacy of β blockers in patients with heart failure plus atrial
fibrillation: An individual-patient data meta-analysis. Lancet.
384:2235–2243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Massie BM, Carson PE, McMurray JJ, Komajda
M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger
C, et al; I-PRESERVE Investigators, . Irbesartan in patients with
heart failure and preserved ejection fraction. N Engl J Med.
359:2456–2467. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo J, Gao X, Peng L, Sun H and Dai G:
Effects of hydrochlorothiazide on cardiac remodeling in a rat model
of myocardial infarction-induced congestive heart failure. Eur J
Pharmacol. 667:314–321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang JL, Yu H, Hou YW, Wang K, Bi WS,
Zhang L, Wang Q, Li P, Yu ML and Zhao XX: Impact of long-term
potassium supplementation on thiazide diuretic-induced
abnormalities of glucose and uric acid metabolisms. J Hum
Hypertens. 32:301–310. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mowla MM and Bustami BB: Brain natriuretic
peptide in heart failure and beyond. Saudi Med J. 27:1457–1461.
2006.PubMed/NCBI
|
|
15
|
Ghali JK, Piña IL, Gottlieb SS, Deedwania
PC and Wikstrand JC; MERIT-HF Study Group, . Metoprolol CR/XL in
female patients with heart failure: Analysis of the experience in
Metoprolol Extended-Release Randomized Intervention Trial in Heart
Failure (MERIT-HF). Circulation. 105:1585–1591. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esquinas AM and Kasai T: Non-invasive
mechanical ventilation for sleep disordered breathing and cardiac
function in chronic heart failure. More CPAP or more ASV? That is
the question. Int J Cardiol. 168:29782013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gregoretti C, Mattei A and Carlucci A:
Noninvasive ventilation outside the critical care unit. Practical
Issues Updates in Anesthesia and Intensive Care. Springer
International Publishing. 139–147. 2015. View Article : Google Scholar
|
|
18
|
Dave C, Turner A, Dretzke J, Bayliss S,
O'Brien D, Jowett S and Moore D: Protocol for a systematic review
and economic evaluation of the clinical and cost-effectiveness of
non-hospital-based non-invasive ventilation (NIV) in patients with
stable end-stage COPD with hypercapnic respiratory failure. Syst
Rev. 3:322014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Panacek EA and Kirk JD: Role of
noninvasive ventilation in the management of acutely decompensated
heart failure. Rev Cardiovasc Med. 3 Suppl 4:S35–S40.
2002.PubMed/NCBI
|
|
20
|
Stoltzfus S: The role of noninvasive
ventilation: CPAP and BiPAP in the treatment of congestive heart
failure. Dimens Crit Care Nurs. 25:66–70. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prescher S, Schoebel C, Koehler K,
Deckwart O, Wellge B, Honold M, Hartmann O, Winkler S and Koehler
F: Prognostic value of serial six-minute walk tests using
tele-accelerometry in patients with chronic heart failure: A
pre-specified sub-study of the TIM-HF-Trial. Eur J Prev Cardiol. 23
Suppl:21–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barth AS, Kumordzie A, Frangakis C,
Margulies KB, Cappola TP and Tomaselli GF: Reciprocal
transcriptional regulation of metabolic and signaling pathways
correlates with disease severity in heart failure. Circ Cardiovasc
Genet. 4:475–483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
No authors listed: 5 action steps for
early heart failure. Early heart failure may be mild but can worsen
quickly. Learn what you can do to keep symptoms in check. Harv
Heart Lett. 24:32014.
|
|
24
|
Pourafkari L, Ghaffari S, Afshar AH, Anwar
S and Nader ND: Predicting outcome in acute heart failure, does it
matter? Acta Cardiol. 70:653–663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonacchi M, Vannini A, Harmelin G,
Batacchi S, Bugetti M, Sani G and Peris A: Inverted-Takotsubo
cardiomyopathy: Severe refractory heart failure in poly-trauma
patients saved by emergency extracorporeal life support. Interact
Cardiovasc Thorac Surg. 20:365–371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patel KP: Role of paraventricular nucleus
in mediating sympathetic outflow in heart failure. Heart Fail Rev.
5:73–86. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berg T: β1-Blockers lower norepinephrine
release by inhibiting presynaptic, facilitating β1-adrenoceptors in
normotensive and hypertensive rats. Front Neurol. 5:512014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Chen P, Hanaoka M, Huang X, Droma
Y and Kubo K: Mechanical ventilation in patients with hypoxemia due
to refractory heart failure. Intern Med. 47:367–373. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Squadrone E, Frigerio P, Fogliati C,
Gregoretti C, Conti G, Antonelli M, Costa R, Baiardi P and Navalesi
P: Noninvasive vs invasive ventilation in COPD patients with severe
acute respiratory failure deemed to require ventilatory assistance.
Intensive Care Med. 30:1303–1310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuhn BT, Bradley LA, Dempsey TM, Puro AC
and Adams JY: Management of mechanical ventilation in decompensated
heart failure. J Cardiovasc Dev Dis. 3:32016.
|
|
31
|
Huang QF, Sheng CS, Li Y, Ma GS, Dai QY
and Wang JG; INCENT Investigators, . Efficacy and safety of a fixed
combination of irbesartan/hydrochlorothiazide in Chinese patients
with moderate to severe hypertension. Drugs R D. 13:109–117. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Croxtall JD and Keating GM:
Irbesartan/Hydrochlorothiazide: In moderate to severe hypertension.
Drugs. 68:1465–1472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chrysant SG, Neutel JM and Ferdinand KC;
INCLUSIVE investigators, . Irbesartan/hydrochlorothiazide for the
treatment of isolated systolic hypertension: A subgroup analysis of
the INCLUSIVE trial. J Natl Med Assoc. 101:300–307. 2009.
View Article : Google Scholar : PubMed/NCBI
|
